Statement
|
1.Date of occurrence of the event:2024/09/27
2.Company name:Daiken Biomedical CO., LTD.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):Subsidiary
4.Reciprocal shareholding ratios:Not Applicable
5.Name of the reporting media:Public Television, Yahoo, and other news reports
6.Content of the report:
A red yeast product from Japan's Kobayashi Pharmaceutical has led to
allegations of kidney damage by consumers in Taiwan who used products made
from this raw material. Today (26th), the Taiwan Consumer Protection
Association officially filed a class action lawsuit on behalf of 55
Taiwanese individuals. The defendants include Daiken Biomedical, the
subsidiary of our company, and five other importers, with the lawsuit
seeking approximately NT$170 million in damages.
7.Cause of occurrence:
The subsidiary, Daiken Biomedical CO., LTD., previously imported the
red yeast raw material from Kobayashi Pharmaceutical to produce CoQ10
red yeast products. Due to the aforementioned incident with Kobayashi red
yeast, consumer disputes and a class action lawsuit have been initiated.
8.Countermeasures:
(1) The subsidiary, Daiken Biomedical CO., LTD., has not yet received
the indictment mentioned in the news. In the past, there has been no
situation where the company failed to respond to consumer complaints.
Daiken will further clarify the details of the report and, upon
receiving the indictment, will consult with the legal department to
draft a defense.
(2) Both our company and the subsidiary have always operated steadily,
and this case does not pose any potential impact on our company's
financial status. Investors are advised to refer to the company's
announcements on the Market Observation Post System for accurate
financial and business information.
9.Any other matters that need to be specified:None.
|